TrialSite Staff | Making Biomedical Research Evidence Accessible to All
May. 18, 2026, 2:30 p.m.
The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold.
This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 observational study, with Sanofi joining a growing coalition of pharmaceutical, diagnostics, imaging, and digital biomarker companies seeking to transform Alzheimer’s diagnosis through blood-based and digital biomarkers.
The importance of the initiative is difficult to overstate.
Alzheimer’s disease and related dementias represent one of the largest emerging medical, economic, and societal threats facing aging populations worldwide. In the United States alone, millions of Americans currently live with Alzheimer’s disease, while costs associated with long-term care, caregiver burden, lost productivity, and institutional support already exceed hundreds of billions of dollars annually. As populations age across North America, Europe, and parts of Asia, those burdens are expected to surge sharply.
Yet diagnosis remains a major challenge.
Current approaches often rely on expensive PET imaging, MRI scans, specialist evaluations, or invasive procedures that limit widespread early detection. Bio-Hermes-002 seeks to address that gap by evaluating combinations of blood-based biomarkers, digital assessments, MRI, and PET imaging across diverse racial and ethnic populations to improve prediction and diagnosis of Alzheimer’s pathology, including amyloid and tau accumulation.
The study also reflects a broader transformation underway in neurodegenerative medicine: the convergence of AI-enabled analytics, biomarker science, cloud-based data sharing, and precision diagnostics.
If successful, studies like Bio-Hermes-002 could help shift Alzheimer’s care from late-stage management toward earlier intervention—potentially reshaping clinical trials, drug development, and patient outcomes worldwide. https://www.trialsitenews.com/a/alzheimers-diagnostics-race-accelerates-as-global-alzheimers-platform-expands-bio-hermes-002-study-db441cfe